BALSAM MEDICA
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At BALSAM MEDICA in Warsaw, much of the clinical research focuses on cardiovascular diseases, especially heart failure, hypertension, and broader cardiovascular disease. These studies are aimed at finding better ways to reduce major heart-related events, improve symptoms, and support long-term heart health.
- Research on heart failure, including both reduced and preserved ejection fraction, to evaluate new treatment options and improve outcomes
- Studies in hypertension and high cardiovascular risk populations to test approaches for better blood pressure control and risk reduction
- Trials in atherosclerotic cardiovascular disease and established cardiovascular disease focused on preventing serious events such as heart attack and stroke
- Research on elevated lipoprotein(a) and other risk factors to improve prevention strategies in people with ongoing cardiovascular risk
Overall, the site is contributing to studies that assess new therapies and combinations designed to lower cardiovascular complications and improve care for patients with complex heart conditions.
Nutritional and Metabolic Diseases
The site also conducts trials in nutritional and metabolic diseases, with a strong emphasis on obesity, overweight, and type 2 diabetes. These studies explore whether new treatments can improve metabolic health while also reducing related cardiovascular and kidney risks.
- Research in obesity and overweight aimed at supporting weight-related health improvements and lowering associated complications
- Studies in type 2 diabetes combined with hypertension and cardiovascular disease to evaluate treatments that may address several linked conditions at once
- Trials examining therapies for people at risk of both heart and kidney problems, with the goal of improving overall disease control
This research reflects a broader effort to test new approaches for people whose metabolic conditions overlap with cardiovascular disease, helping to identify treatments that may offer benefits across multiple health areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Ribocure Pharmaceuticals AB1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in BALSAM MEDICA
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Dose-Ranging Study of AZD5462 in Stable Chronic Heart Failure: A Phase IIb Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial | AstraZeneca AB | Phase II | Not Recruiting | Jul 2024 | Jan 2026 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apixaban | 1 | Unknown | — | — |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
